Tubular TNFSF4/OX40L promotes fibrotic transition following acute kidney injury via activating GSK-3α.

IF 10.5 2区 医学 Q1 PHARMACOLOGY & PHARMACY
Kexin Yang, Lei Zhang, Ziyi Xiong, Yingying Lu, Shumin Zhang, Yifei Liu, Lei Zhang, Juan Cai, Chengyuan Tang, Yu Liu, Tuo Deng, Lin Sun, Fuyou Liu, Shaobin Duan, Li Xiao
{"title":"Tubular TNFSF4/OX40L promotes fibrotic transition following acute kidney injury via activating GSK-3α.","authors":"Kexin Yang, Lei Zhang, Ziyi Xiong, Yingying Lu, Shumin Zhang, Yifei Liu, Lei Zhang, Juan Cai, Chengyuan Tang, Yu Liu, Tuo Deng, Lin Sun, Fuyou Liu, Shaobin Duan, Li Xiao","doi":"10.1016/j.phrs.2026.108230","DOIUrl":null,"url":null,"abstract":"<p><p>Acute kidney injury (AKI) often progresses to chronic kidney disease (CKD) characterized by renal fibrosis, yet the regulatory mechanisms driving this transition remain elusive. Here, it is demonstrated that tumor necrosis factor superfamily member 4 (TNFSF4/OX40L) significantly upregulates in proximal tubular cells (PTCs) from patients with CKD and in murine models of AKI-CKD transition induced by unilateral ischemia-reperfusion injury (uIRI) or repeated low-dose cisplatin. Elevated TNFSF4 levels correlates positively with the severity of tubulointerstitial injury and negatively with estimated glomerular filtration rate. Functionally, proximal tubule-specific deletion of Tnfsf4 markedly ameliorates tubular damage, renal inflammation and interstitial fibrosis in both AKI-CKD models. Furthermore, anti-TNFSF4 monoclonal antibody exerts its therapeutic effects in AKI-CKD mice suffering from uIRI. Conversely, overexpression of TNFSF4 exacerbates pro-fibrotic responses in PTCs under TGF-β1 or chronic hypoxia conditions. Mechanistically, immunoprecipitation-mass spectrometry identifies an interaction between TNFSF4 and glycogen synthase kinase-3α (GSK-3α). TNFSF4 blocks synaptotagmin-like protein 4 (SYTL4)-mediated ubiquitination of GSK-3α, prolongs its half-life, and sustains profibrotic signaling, effects reversed by GSK-3α knockdown. Collectively, these results uncover a previously unrecognized TNFSF4-GSK-3α axis as a key proximal tubule-intrinsic driver of AKI-CKD progression, and propose targeting this pathway as a promising therapeutic strategy to mitigate renal fibrosis and halt AKI-CKD transition.</p>","PeriodicalId":19918,"journal":{"name":"Pharmacological research","volume":" ","pages":"108230"},"PeriodicalIF":10.5000,"publicationDate":"2026-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacological research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.phrs.2026.108230","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Acute kidney injury (AKI) often progresses to chronic kidney disease (CKD) characterized by renal fibrosis, yet the regulatory mechanisms driving this transition remain elusive. Here, it is demonstrated that tumor necrosis factor superfamily member 4 (TNFSF4/OX40L) significantly upregulates in proximal tubular cells (PTCs) from patients with CKD and in murine models of AKI-CKD transition induced by unilateral ischemia-reperfusion injury (uIRI) or repeated low-dose cisplatin. Elevated TNFSF4 levels correlates positively with the severity of tubulointerstitial injury and negatively with estimated glomerular filtration rate. Functionally, proximal tubule-specific deletion of Tnfsf4 markedly ameliorates tubular damage, renal inflammation and interstitial fibrosis in both AKI-CKD models. Furthermore, anti-TNFSF4 monoclonal antibody exerts its therapeutic effects in AKI-CKD mice suffering from uIRI. Conversely, overexpression of TNFSF4 exacerbates pro-fibrotic responses in PTCs under TGF-β1 or chronic hypoxia conditions. Mechanistically, immunoprecipitation-mass spectrometry identifies an interaction between TNFSF4 and glycogen synthase kinase-3α (GSK-3α). TNFSF4 blocks synaptotagmin-like protein 4 (SYTL4)-mediated ubiquitination of GSK-3α, prolongs its half-life, and sustains profibrotic signaling, effects reversed by GSK-3α knockdown. Collectively, these results uncover a previously unrecognized TNFSF4-GSK-3α axis as a key proximal tubule-intrinsic driver of AKI-CKD progression, and propose targeting this pathway as a promising therapeutic strategy to mitigate renal fibrosis and halt AKI-CKD transition.

肾小管TNFSF4/OX40L通过激活GSK-3α促进急性肾损伤后的纤维化转变。
急性肾损伤(AKI)经常发展为以肾纤维化为特征的慢性肾脏疾病(CKD),然而驱动这一转变的调控机制仍然难以捉摸。本研究表明,肿瘤坏死因子超家族成员4 (TNFSF4/OX40L)在CKD患者和单侧缺血再灌注损伤(uIRI)或重复低剂量顺铂诱导的AKI-CKD过渡的小鼠模型中的近端小管细胞(ptc)中显著上调。TNFSF4水平升高与小管间质损伤的严重程度呈正相关,与估计的肾小球滤过率呈负相关。功能上,近端小管特异性缺失Tnfsf4可显著改善AKI-CKD模型中的小管损伤、肾脏炎症和间质纤维化。此外,抗tnfsf4单克隆抗体在AKI-CKD小鼠uIRI中发挥其治疗作用。相反,在TGF-β1或慢性缺氧条件下,TNFSF4的过表达会加剧ptc的促纤维化反应。机制上,免疫沉淀-质谱法鉴定了TNFSF4和糖原合成酶激酶3α (GSK-3α)之间的相互作用。TNFSF4阻断SYTL4介导的GSK-3α泛素化,延长其半衰期,维持促纤维化信号传导,这种作用被GSK-3α敲低逆转。总的来说,这些结果揭示了以前未被识别的TNFSF4-GSK-3α轴是AKI-CKD进展的关键近端小管内在驱动因素,并提出靶向该途径作为一种有希望的治疗策略来减轻肾纤维化和阻止AKI-CKD转变。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Pharmacological research
Pharmacological research 医学-药学
CiteScore
18.70
自引率
3.20%
发文量
491
审稿时长
8 days
期刊介绍: Pharmacological Research publishes cutting-edge articles in biomedical sciences to cover a broad range of topics that move the pharmacological field forward. Pharmacological research publishes articles on molecular, biochemical, translational, and clinical research (including clinical trials); it is proud of its rapid publication of accepted papers that comprises a dedicated, fast acceptance and publication track for high profile articles.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书